{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:14:44Z","timestamp":1792401284512,"version":"4.4.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To describe the demographics and phenotypes of malignancies-associated dermatomyositis (MADM) in east China and pinpoint potential factors indicative of malignancies in patients with dermatomyositis and establish a predictive model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively analyzed clinical data from 134 patients with adult-onset dermatomyositis hospitalized between January 2019 and May 2022 in one comprehensive hospital. Clinical data including disease course, initial symptoms and signs, and demographic information were retrieved from the Electronic Medical Records System. Other parameters including myositis-specific autoantibodies profiles, ferritin, sedimentation, etc. were all referable. Multivariable multinomial logistic regression was employed to simulate a model to predict cancer risks. Receiver operating characteristic curve was adopted to evaluate the potency of the model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>134 patients with adult-onset dermatomyositis were aptly enrolled in this study based on inclusive and exclusive criteria: 12 (8.96%) with malignancies, 57 (42.53%) with aberrant tumor biomarkers but no malignancies, 65 (48.51%) with neither malignancies nor abnormal tumor biomarkers. Senior diagnostic age, higher LDH, higher ferritin, positive anti-TIF1\u03b3 and anti-Mi2 rather than anti-NXP2 autoantibodies were positive indicators of malignancies. Additionally, neither initial complaints nor signs were found to be correlated to a tendency towards malignancies. Digestive system, nasopharyngeal, and lung malignancies were mostly documented in east China. One multivariable multinomial logistic regression model was established to predict the phenotypes of dermatomyositis on the basis of potential malignancies and the overall sensitivity and specificity was satisfactory.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Positivity of anti-TIF1\u03b3 and anti-Mi2 autoantibodies are highly indicative of malignancies while the role of anti-NXP2 autoantibody in MADM in the Chinese population remains unclear. The phenotypes of malignancies can be predicted through the model and the predictive power is sufficient. More attention should be paid to malignancies screening in patients with aberrant tumor biomarkers but no malignancies, particularly digestive system, nasopharyngeal, and lung malignancies in patients with dermatomyositis but without malignancies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1200804","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T05:14:51Z","timestamp":1686201291000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Malignancy in dermatomyositis: a mono-centric retrospective study of 134 patients in China and a potential predictive model"],"prefix":"10.3389","volume":"10","author":[{"given":"Zhuang-Li","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-cheng","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia-Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yong","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/ddg.14566","article-title":"Characteristics of dermatomyositis patients with and without associated malignancy","volume":"19","author":"Lauinger","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e22978","DOI":"10.7759\/cureus.22978","article-title":"The role of myositis-specific autoantibodies in the dermatomyositis spectrum","volume":"14","author":"Marasandra Ramesh","year":"2022","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1111\/bjd.18618","article-title":"Age-and sex-appropriate cancer screening risks missing most occult malignancies in young patients with dermatomyositis","volume":"182","author":"Kundrick","year":"2020","journal-title":"Br J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s12016-022-08922-4","article-title":"Autoantibody markers of increased risk of malignancy in patients with dermatomyositis","volume":"63","author":"Marz\u0119cka","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.12865\/CHSJ.47.03.07","article-title":"A study on dermatomyositis and the relation to malignancy","volume":"47","author":"Tudorancea","year":"2021","journal-title":"Curr Health Sci J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/9141420","article-title":"Biomarkers in adult dermatomyositis: tools to help the diagnosis and predict the clinical outcome","volume":"2019","author":"Cassius","year":"2019","journal-title":"J Immunol Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jdermsci.2021.10.003","article-title":"Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1gamma antibodies","volume":"104","author":"Ly","year":"2021","journal-title":"J Dermatol Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13256-021-02664-1","article-title":"Anti-transcription intermediary factor 1 gamma (TIF1gamma) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature","volume":"15","author":"Ono","year":"2021","journal-title":"J Med Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European league against rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/ajd.13892","article-title":"The associations between myositis autoantibodies and clinical presentations in dermatomyositis","volume":"63","author":"Su","year":"2022","journal-title":"Australas J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.amjmed.2022.01.016","article-title":"Paraneoplastic Dermatomyositis","volume":"135","author":"Orton","year":"2022","journal-title":"Am J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3899\/jrheum.140566","article-title":"Polymyositis\/dermatomyositis and malignancy risk: a meta analysis study","volume":"42","author":"Yang","year":"2015","journal-title":"J Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2020.02.061","article-title":"Malignancy in dermatomyositis: a retrospective study of 201 patients seen at the University of Pennsylvania","volume":"83","author":"Bowerman","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1203475416665601","article-title":"Risk of malignancy in Dermatomyositis and Polymyositis","volume":"21","author":"Qiang","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1007\/s12253-019-00756-4","article-title":"Retrospective analysis of cancer-associated myositis patients over the past 3 decades in a Hungarian myositis cohort","volume":"26","author":"Andras","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e12626","DOI":"10.7717\/peerj.12626","article-title":"Development and validation of a nomogram risk prediction model for malignancy in dermatomyositis patients: a retrospective study","volume":"9","author":"Zhong","year":"2021","journal-title":"Peer J"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MD.0b013e31819da352","article-title":"Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis","volume":"88","author":"Fardet","year":"2009","journal-title":"Medicine (Baltimore)"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40257-015-0120-1","article-title":"Cancer risk in dermatomyositis: a meta-analysis of cohort studies","volume":"16","author":"Olazagasti","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet (London, England)"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/j.1365-4632.2011.05449.x","article-title":"A comparative study of clinical characteristics, work-up, treatment, and association to malignancy in dermatomyositis between two tertiary skin centers in the USA and Singapore","volume":"52","author":"Yosipovitch","year":"2013","journal-title":"Int J Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e21733","DOI":"10.1097\/MD.0000000000021733","article-title":"Malignancy in dermatomyositis: a retrospective paired case-control study of 202 patients from Central China","volume":"99","author":"Chang","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.3892\/ol.2018.9409","article-title":"Characteristics and predictors of malignancy in dermatomyositis: analysis of 239 patients from northern China","volume":"16","author":"Liu","year":"2018","journal-title":"Oncol Lett"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s10067-016-3296-8","article-title":"Malignancy in dermatomyositis and polymyositis: analysis of 192 patients","volume":"35","author":"Fang","year":"2016","journal-title":"Clin Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"432","DOI":"10.21037\/atm-20-5215","article-title":"Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?","volume":"9","author":"Khanna","year":"2021","journal-title":"Ann Transl Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12016-015-8496-5","article-title":"Cutaneous manifestations in dermatomyositis: key clinical and serological features-a comprehensive review","volume":"51","author":"Muro","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/rheumatology\/kez572","article-title":"Anti-TIF1-gamma autoantibodies: warning lights of a tumour autoantigen","volume":"59","author":"De Vooght","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/BOR.0000000000000329","article-title":"Recent advances in dermatomyositis-specific autoantibodies","volume":"28","author":"Fujimoto","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s12016-022-08944-y","article-title":"Autoantibodies and cancer association: the case of systemic sclerosis and dermatomyositis","volume":"63","author":"Fiorentino","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/acr.23188","article-title":"Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients","volume":"69","author":"Albayda","year":"2017","journal-title":"Arthritis Care Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10067-016-3453-0","article-title":"Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis","volume":"36","author":"Ceribelli","year":"2017","journal-title":"Clin Rheumatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.jaad.2020.03.058","article-title":"Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: a classic skin rash with a necrotizing myositis and high risk of malignancy","volume":"83","author":"Monseau","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/diseases9010021","article-title":"Diagnostic and prognostic value of CEA and CA19-9 in colorectal cancer","volume":"9","author":"Lakemeyer","year":"2021","journal-title":"Diseases"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1186\/s12885-017-3738-y","article-title":"Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer","volume":"17","author":"Feng","year":"2017","journal-title":"BMC Cancer"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"188503","DOI":"10.1016\/j.bbcan.2021.188503","article-title":"Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer","volume":"1875","author":"Zhang","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3892\/ol.2020.12117","article-title":"Diagnostic value and clinical significance of circulating miR-650 and CA211 in detecting of gastric carcinoma","volume":"20","author":"Chen","year":"2020","journal-title":"Oncol Lett"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-94-017-7215-0_9","article-title":"Neuron-specific enolase as a biomarker: biochemical and clinical aspects","volume":"867","author":"Isgro","year":"2015","journal-title":"Adv Exp Med Biol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1200804\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T05:14:56Z","timestamp":1686201296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1200804\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":38,"alternative-id":["10.3389\/fmed.2023.1200804"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1200804","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"article-number":"1200804"}}